Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

John S. Patton

Nektar Therapeutics

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and viral diseases. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

Pearl Therapeutics

Deerfield

SFJ Pharmaceuticals

AstraZeneca

New Enterprise Associates

At #JPM2024 next week, Nektar’s management team will present on exciting company updates across our #immunology and #immunooncology pipelines. Learn more about us: https://bit.ly/47nZHVe

New preclinical data presented at #ASH23 by our collaborators at NYMC highlight that NKTR-255, in combination with obinutuzumab, expanded NK cells and enhanced antibody-dependent cellular cytotoxicity against rituximab-resistant Burkitt lymphoma cells. Learn more: https://bit.ly/48fE3DO

We’re celebrating Mary Tagliaferri, MD, Nektar’s Chief Medical Officer, who was recently named as one of Inc. Magazine’s 10 Most Eminent Women Leaders in Healthcare 2023. Learn more about Mary and the vital role she plays at Nektar directing clinical strategy, operations and medical affairs: https://bit.ly/3smei5l

At #EADVCongress this week, we presented new and encouraging responder data in late-breaking news oral presentation for Rezpegaldesleukin, our first-in-class selective T-reg therapy, in patients with #atopicdermatitis, also being studied in #alopeciaareata. Full press release: https://bit.ly/3M1sIye

We’re gearing up for #EADVCongress next week, where Nektar will have two presentations for Rezpegaldesleukin, our first-in-class selective regulatory T-cell therapy, being studied in #atopicdermatitis and #alopeciaareata. Additional details: https://bit.ly/3ZDSoXx

Metric
Company Name	Nektar Therapeutics
Symbol	NKTR
MSH ID	COM:NEKTAR
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	137
Website	nektar.com
LinkedIn	nektar-therapeutics
Founders

Metric
Market Cap	244.75M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	90.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	53.48M
EBITDA	-129.61M
Operating Income	-137.43M
Net Income	-276.06M
EPS	-1.45
Diluted EPS	-1.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.63
Operating Profit Margin	-1.57
EBITDA Margin	-1.44
Net Profit Margin	-1.90
Return on Equity	-1.15
Return on Assets	-0.44
Return on Capital Employed	-0.47

COM:NEKTAR

Nektar Therapeutics

Last Close

1.01

22/11 21:00

Market Cap

244.75M

Beta: -

Volume Today

4.63M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.37
P/B Ratio	0.69
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.73
EV Multiple	0.36

Metric
Days Sales Outstanding	9.11
Days Payables Outstanding	36.68
Days Inventory Outstanding	174.04
Operating Cycle	190.17
Cash Conversion Cycle	99.47
Asset Turnover	0.27

Metric
Operating Cash Flow	-192.61M
Free Cash Flow	-193.47M
Cash Flow to Debt	-1.36
Operating Cash Flow/Sales	-1.88
Free Cash Flow Yield	-1.90

Metric
Cash & Equivalents	20.16M
Accounts Receivable	4.78M
Inventory	16.10M
Goodwill
Debt to Capitalization	0.62
Debt to Assets	0.27
Current Ratio	7.66
Quick Ratio	5.97

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.35
R&D to Revenue	1.35
SG&A to Revenue	0.93